RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Windtree Therapeutics Stock

Windtree Therapeutics Stocks 2024

Windtree Therapeutics Stocks

3.88 M

Ticker

WINT

ISIN

US97382D3035

WKN

A2P3ZQ

In 2024, Windtree Therapeutics had 3.88 M outstanding stocks, a 0% change from the 3.88 M stocks in the previous year.

The Windtree Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e3.88
2028e3.88
2027e3.88
2026e3.88
2025e3.88
2024e3.88
20233.88
20220.04
20210.03
20200.02
20190.01
20180
20170
20160
20150
20140
20130
20120
2011-
2010-
2009-
2008-
2007-
2006-
2005-
2004-

Windtree Therapeutics shares outstanding

The number of shares was Windtree Therapeutics in 2023 — This indicates how many shares 3.876 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Windtree Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Windtree Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Windtree Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Windtree Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Windtree Therapeutics Aktienanalyse

What does Windtree Therapeutics do?

Windtree Therapeutics is an emerging biotechnology company based in Pittsburgh, Pennsylvania. The company was founded in 2011 and specializes in the development of innovative therapies for respiratory diseases. Windtree Therapeutics aims to improve the lives of millions of people worldwide by providing effective and safe medications. History: Windtree Therapeutics has a history that dates back to 1990 when it was founded as Advanced Inhalation Research, focusing on the development of therapies for respiratory diseases. After several rounds of financing and mergers, the company was eventually revived as Windtree Therapeutics. Since then, the company has developed and marketed a range of innovative therapies that improve the lives of millions of patients with respiratory diseases. Business model: Windtree Therapeutics is a biotechnology company focused on the development and commercialization of therapies for respiratory diseases. The company has a strong ethos for innovation and works closely with leading medical and scientific experts to develop high-quality and safe products. The company holds a variety of patents and unique technologies that allow it to improve its competitive position in the industry. Segments: Windtree Therapeutics operates in two business segments: PneumRX® Bronchial Tubes and KL4-Surfactant Technology. PneumRX® Bronchial Tubes: One of Windtree Therapeutics' main segments is the PneumRX® Bronchial Tube technology. This technology aims to improve the lives of patients with chronic obstructive pulmonary disease (COPD). The PneumRX® tubes are used as minimally invasive procedures to open the lumen of the bronchial tubes and facilitate breathing. The technology has already been used in thousands of patients worldwide and is highly regarded by physicians. KL4-Surfactant Technology: Windtree Therapeutics is also known for its KL4-Surfactant Technology, which aims to treat respiratory distress syndrome in newborns. The company has already conducted a number of clinical studies, and the results have been very promising. The KL4-Surfactant Technology is considered one of the most promising treatment options for respiratory problems in newborns. Products: Windtree Therapeutics has a range of products on the market, including: Aer-OS Nitric Oxide Inhalation Device: The Aer-OS Nitric Oxide Inhalation Device is a medical device for patients with pulmonary hypertension. It is the first and only portable nitric oxide inhalation device approved for use at home and on-the-go. The device is used to facilitate breathing and improve patients' quality of life. PneumRX® Bronchial Tubes: The PneumRX® Bronchial Tube technology has already been performed in thousands of patients and is highly regarded by physicians. The technology aims to open the lumen of the bronchial tubes and facilitate breathing. The procedures are minimally invasive and result in minimal injuries. Patients often experience significant improvement in their breathing and overall well-being. KL4-Surfactant Technology: Windtree Therapeutics' KL4-Surfactant Technology is a promising treatment option for respiratory problems in newborns. The technology aims to stimulate lung growth and facilitate breathing. The results of clinical studies have been very promising, and the treatment is considered one of the most promising treatment options for respiratory problems in newborns. In conclusion, Windtree Therapeutics is an emerging biotechnology company with a strong ethos for innovation and the development of therapies for respiratory diseases. The PneumRX® Bronchial Tube technology and KL4-Surfactant Technology are two of the company's main segments. Both technologies are promising and have the potential to improve the lives of millions of patients worldwide. Windtree Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Windtree Therapeutics's Shares Outstanding

Windtree Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Windtree Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Windtree Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Windtree Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Windtree Therapeutics stock

How many stocks are there of Windtree Therapeutics?

The current number of stocks of Windtree Therapeutics is 3.88 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Windtree Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Windtree Therapeutics evolved in recent years?

The number of shares of Windtree Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Windtree Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Windtree Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Windtree Therapeutics pay?

Over the past 12 months, Windtree Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Windtree Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Windtree Therapeutics?

The current dividend yield of Windtree Therapeutics is .

When does Windtree Therapeutics pay dividends?

Windtree Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Windtree Therapeutics?

Windtree Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Windtree Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Windtree Therapeutics located?

Windtree Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Windtree Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Windtree Therapeutics from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did Windtree Therapeutics pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of Windtree Therapeutics in the year 2023?

In the year 2023, Windtree Therapeutics distributed 0 USD as dividends.

In which currency does Windtree Therapeutics pay out the dividend?

The dividends of Windtree Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Windtree Therapeutics

Our stock analysis for Windtree Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Windtree Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.